Invectys will be attending the AACR Annual Meeting 2019. The AACR (American Association for cancer Research) Annual Meeting program covers the latest discoveries…
Invectys secures €15 million equity financing to advance lead program INVAC-1 into groundbreaking phase II clinical trial in CLL Financing complements the…
January 7 – 10, 2019 J.P. Morgan 37th Annual Healthcare Conference 2019 San-Francisco The annual J.P. Morgan Healthcare Conference is the largest and most…
Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1 After a recent capital raise of 4.3 M€s another…
Après le succès de sa Phase I, Invectys lève 4.3 Millions d’Euros permettant la rentrée en Phase II de ses deux vaccins anticancéreux Paris, le 12…
Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…
Invectys will attend to the 18th annual BIO€QUITY Europe Meet Invectys there ! More information: invest@invectys.com 18TH ANNUAL BIO€QUITY EUROPE Bio€quity…
Invectys at the Third International Symposium on Immunotherapy organised by The Institute for Cancer Vaccines & Immunotherapy (previously known as the Cancer…
